Die Größe des Marktes für antivirale Arzneimittelresistenzen wird bis 2031 voraussichtlich 6,35 Milliarden US-Dollar erreichen, gegenüber 3,44 Milliarden US-Dollar im Jahr 2023. Es wird erwartet, dass der Markt im Zeitraum 2023–2031 eine jährliche Wachstumsrate von 7,9 % verzeichnen wird. Die steigende Häufigkeit von Lebererkrankungen, die Verbreitung von HIV und AIDS sowie die Nachfrage nach hochwertigen Produkten in Schwellenländern dürften weiterhin wichtige Trends auf dem Markt bleiben.
Marktanalyse für antivirale Arzneimittelresistenzen
Die Prävalenz von HIV/AIDS hat in den letzten Jahren weltweit zugenommen. Das erworbene Immundefizienzsyndrom (AIDS) ist eine chronische, potenziell lebensbedrohliche Erkrankung, die durch ein humanes Immundefizienzvirus (HIV) verursacht wird. Das Virus ist für die Schädigung des Immunsystems verantwortlich, wobei HIV die Fähigkeit des Körpers beeinträchtigt, die Krankheitserreger zu bekämpfen. Wenn HIV in den Körper eindringt, entwickelt sich innerhalb eines Monats eine grippeähnliche Erkrankung. Diese Krankheit wird als primäre oder akute HIV-Infektion bezeichnet, die einige Wochen andauern kann. Nach den vom US-Gesundheitsministerium bereitgestellten und vom Minority AIDS Initiative Fund ( SMAIF ) des Ministers unterstützten Daten werden im Jahr 2022 ca. Weltweit lebten 39 Millionen Menschen mit HIV/AIDS. Die überwiegende Mehrheit der Menschen mit HIV lebt in Ländern mit niedrigem und mittlerem Einkommen. Laut dem Bericht „India HIV Estimation 2017“ (National Informatics Center ) wird die HIV-Prävalenz in Indien beispielsweise auf 0,22 % (0,16 %–0,30 %) geschätzt. Darüber hinaus wird die HIV-Prävalenz bei Erwachsenen bei Männern auf 0,25 % (0,18–0,34 %) und bei Frauen auf 0,19 % (0,14–0,25) geschätzt. Daher wird erwartet, dass die Fälle von Virusinfektionen im Land die Nachfrage nach dem Markt für antivirale Arzneimittelresistenzen im Prognosezeitraum ankurbeln werden
Marktübersicht für antivirale Arzneimittelresistenzen
Rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS are boosting the growth of the market over the years. Also, the increase in the emerging market is likely to have a positive impact on the demand for the market during the forecast period. However, the growth of the market is restrained by a factor such as alternative approaches. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Hence, the factors as mentioned above are anticipated to fuel the growth of North America antiviral drug resistance market during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Antiviral Drug Resistance Market: Strategic Insights
CAGR (2023 - 2031)7.9%- Market Size 2023
US$ 3.44 Billion - Market Size 2031
US$ 6.35 Billion
Market Dynamics
- Risisng Incidences of Hepatatic Diseases to Favor Market
- Increasing Prevalence of HIV/AIDs
- Increasing Healthcare Expenditures in Emerging Markets
Key Players
- AccuBioTech Co., Ltd.;
- ACON Laboratories, Inc.;
- Siemens AG;
- BioMérieux SA;
- Bio-Rad Laboratories, Inc.;
- Danaher;
- Abbott;
- BD ;
- F Hoffmann-La Roche Ltd.;
- Trinity Biotech
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product - Kits & Reagents
- Instruments
Disease Indication - Human Immunodeficiency Virus
Technology - Immunodiagnostics
- Polymerase Chain Reaction
End User - Hospitals & Clinics
- Pathology or Diagnostic Laboratories
- Research Institutes
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Antiviral Drug Resistance Market Drivers and Opportunities
Rising Incidences of Hepatic Diseases to Favor Market
Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems. The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
Increasing Healthcare Expenditures in Emerging Markets
The increasing healthcare expenditure in emerging economies such as Asia Pacific and South and Central America are enabling researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next-generation sequencing, and others. Several organizations such as, National Cancer Institute (NCI) funded for HIV and AIDS Malignancies Research to study about how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer. China, Japan, Brazil and other emerging nations are spending heavily on healthcare expenditure to establish their presence in the market as well as to ensure the appropriate use of instruments and reagents used in hospitals and research institutes, pathological labs and other destinations in their respective countries.
Antiviral Drug Resistance Market Report Segmentation Analysis
Key segments that contributed to the derivation of the antiviral drug resistance market analysis are type, disease indication, technology, and end users.
- Based on type, the antiviral drug resistance market is divided into into kits and reagents and instruments. The kits and reagents segment held the largest share of the market in 2023.
- By disease indication, the market is segmented into HIV, hepatitis and Cytomegalovirus (CMV). The HIV segment held the largest share of the market in 2023.
- In terms of technology, the market is segmented into immunodiagnostics, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. The immunodiagnostics segment held a significant share of the market in 2023.
- Basierend auf den Endverbrauchern ist der Markt für antivirale Arzneimittelresistenzen in Krankenhäuser und Kliniken, Pathologie- oder Diagnoselabore und Forschungsinstitute unterteilt. Das Segment Krankenhäuser und Kliniken hielt im Jahr 2023 den größten Marktanteil.
Analyse des Marktanteils antiviraler Arzneimittelresistenzen nach Geografie
Der geografische Umfang des Marktberichts über antivirale Arzneimittelresistenzen ist hauptsächlich in fünf Regionen unterteilt: Nordamerika, Asien-Pazifik, Europa, Naher Osten und Afrika sowie Süd- und Mittelamerika. Geographisch gesehen hat Nordamerika den größten Marktanteil am Markt für High-Flow-Nasenkanülen. Aufgrund verschiedener Faktoren wie der Verbreitung von Virusinfektionen wie HIV und Hepatitis, dem Vorhandensein nationaler Programme und der Finanzierung durch staatliche Stellen wird erwartet, dass die Marktnachfrage im Prognosezeitraum erheblich wachsen wird. Die HIV-Prävalenz in den USA hat in den letzten Jahren zugenommen. Nach Angaben des US-Gesundheitsministeriums, das vom Minority AIDS Initiative Fund (SMAIF) des Ministers unterstützt wird, wurden im Jahr 2021 fast 32.100 Amerikaner neu mit HIV infiziert. Der asiatisch-pazifische Raum wird voraussichtlich mit der höchsten CAGR wachsen kommende Jahre.
Umfang des Marktberichts über antivirale Arzneimittelresistenzen
| Berichtsattribut | Einzelheiten |
|---|---|
| Marktgröße im Jahr 2023 | 3,44 Milliarden US-Dollar |
| Marktgröße bis 2031 | 6,35 Milliarden US-Dollar |
| Globale CAGR (2023–2031) | 7,9 % |
| Historische Daten | 2021-2022 |
| Prognosezeitraum | 2024-2031 |
| Abgedeckte Segmente | Nach Produkt
|
| Abgedeckte Regionen und Länder | Nordamerika
|
| Marktführer und wichtige Unternehmensprofile |
|
- Beispiel-PDF zeigt die Inhaltsstruktur und die Art der Informationen mit qualitativer und quantitativer Analyse.
Marktnachrichten und aktuelle Entwicklungen zur antiviralen Arzneimittelresistenz
Der Markt für antivirale Arzneimittelresistenzen wird durch die Erfassung qualitativer und quantitativer Daten aus der Primär- und Sekundärforschung bewertet, zu denen wichtige Unternehmenspublikationen, Verbandsdaten und Datenbanken gehören. Nachfolgend sind einige der Entwicklungen auf dem Markt für antivirale Arzneimittelresistenzen aufgeführt:
- – Die Janssen Pharmaceutical Companies von Johnson & Johnson (Janssen) gaben heute die Veröffentlichung neuer Daten in der Zeitschrift Nature bekannt, die zeigen, dass ein klinischer Kandidat im Frühstadium (JNJ-1802) einen starken Schutz gegen Dengue-Fieber bei nichtmenschlichen Primaten und Mäusen bietet. Das erste antivirale Mittel seiner Klasse, das sich in einer klinischen Phase-1-Studie am Menschen als sicher und gut verträglich erwiesen hat, geht nun in klinische Phase-2-Studien zur Vorbeugung und Behandlung von Denguefieber über. (Quelle: Johnson & Johnson, Pressemitteilung, März 2023)
- Cipla Limited gab bekannt, dass ihm vom Drug Controller General of India (DCGI) die Genehmigung zur Notfallverwendung (Emergency Use Authorisation, EUA) für die Einführung von Molnupiravir im Land erteilt wurde. Cipla plant, Molnupiravir unter dem Markennamen Cipmolnu® auf den Markt zu bringen. Molnupiravir ist das erste orale antivirale Mittel, das von der britischen Arzneimittel- und Gesundheitsbehörde (MHRA) für die Behandlung von leichtem bis mittelschwerem COVID-19 mit hohem Risiko für die Entwicklung einer schweren Erkrankung zugelassen wurde. (Quelle: Cipla, Pressemitteilung, Mai 2021)
Berichterstattung und Ergebnisse des Marktberichts über antivirale Arzneimittelresistenzen
Der Bericht „Marktgröße und Prognose für antivirale Arzneimittelresistenzen (2021–2031)“ bietet eine detaillierte Analyse des Marktes und deckt die folgenden Bereiche ab:
- Marktgröße und -prognose für antivirale Arzneimittelresistenz auf globaler, regionaler und Länderebene für alle wichtigen Marktsegmente, die im Geltungsbereich abgedeckt sind
- Markttrends für antivirale Arzneimittelresistenz sowie Marktdynamiken wie Treiber, Einschränkungen und wichtige Chancen
- Detaillierte PEST/Porter's Five Forces- und SWOT-Analyse
- Marktanalyse für antivirale Arzneimittelresistenz, die wichtige Markttrends, globale und regionale Rahmenbedingungen, Hauptakteure, Vorschriften und aktuelle Marktentwicklungen abdeckt
- Branchenlandschafts- und Wettbewerbsanalyse, die Marktkonzentration, Heatmap-Analyse, prominente Akteure und aktuelle Entwicklungen auf dem Markt für antivirale Arzneimittelresistenz umfasst
- Detaillierte Firmenprofile
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Based on geography, the antiviral drug resistance market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global antiviral drug resistance market. Asia Pacific is expected to register the highest CAGR in the antiviral drug resistance market during 2023–2031
Risisng in the incidences of hepatitis diseases followed by increasing prevalence of HIV and AIDS largely drive the antiviral drug resistance market size
The Antiviral Drug Resistance market majorly consists of players such AccuBioTech Co., Ltd.; ACON Laboratories, Inc.; Siemens AG; BioMérieux SA; Bio-Rad Laboratories, Inc.; Danaher; Abbott; BDF. Hoffmann-La Roche Ltd.; and Trinity Biotech.
The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031
The market is expected to register a CAGR of 7.9% during 2023–2031
Trends and growth analysis reports related to Life Sciences : READ MORE..
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For